吡格列酮对胰岛素抵抗HepG2细胞模型的药理学评价

被引:33
作者
陈秋 [1 ]
夏永鹏 [2 ]
邱宗荫 [2 ]
机构
[1] 泸州医学院附属医院内分泌科
[2] 重庆医科大学药学系
关键词
胰岛素抵抗; 细胞模型; HepG2细胞; 吡格列酮; 评价;
D O I
暂无
中图分类号
R965 [实验药理学];
学科分类号
摘要
目的应用高胰岛素诱导培养HepG2细胞,建立胰岛素抵抗的细胞模型。并探讨吡格列酮对该模型胰岛素敏感性和糖代谢的影响。方法将HepG2细胞置于5×10-7mol.L-1胰岛素培养液中16 h,采用3H-D-葡萄糖参入试验观察高胰岛素对HepG2细胞葡萄糖摄取率的影响。模型建立后,培养液中加入吡格列酮共同孵育,观察吡格列酮对胰岛素抵抗细胞模型葡萄糖摄取率和葡萄糖消耗量的影响。结果高胰岛素诱导培养的HepG2细胞葡萄糖参入率明显低于未用高胰岛素诱导的HepG2细胞(对照细胞)。将高胰岛素诱导培养的HepG2细胞置于不含胰岛素的培养液中60 h,其细胞葡萄糖摄取率仍明显低于对照细胞。含有吡格列酮(浓度为1×10-6~1×10-4mol.L-1)的胰岛素抵抗HepG2细胞的葡萄糖参入率与葡萄糖消耗量明显高于不含吡格列酮的胰岛素抵抗HepG2细胞(P<0.01)。结论将HepG2置于5×10-7mol.L-1胰岛素环境中16 h,该细胞对胰岛素的生物学效应产生抵抗,其胰岛素抵抗状态可维持60 h。该方法较为简便、易行、重复性好、成功率高,可广泛用于胰岛素抵抗的研究。吡格列酮能增加胰岛素抵抗模型细胞的胰岛素敏感性,并能明显改善糖代谢。
引用
收藏
页码:248 / 251
页数:4
相关论文
共 9 条
  • [1] Insulin sensitisation in the treatment ofType d iabetes. Tadayyon M,Sm ith SA. Expert Opinion on Investigational Drugs . 2003
  • [2] Thiazolid ined iones in d iabetes:Current status and futureoutlook. Camp HS. Curr Opin Investig Drug,s . 2003
  • [3] Dexamethasone induction ofhypertension and d iabetes is PPAR-alpha dependent in LDL re-ceptor-nullm ice. BernalMC,W eng S,Finck BNet al. NatM ed . 2003
  • [4] Diabetes
    [P].
  • [5] l E ffect of troglitazone on vas-cular and glucose metabolic actions of insulin in high-sucrose-fedrats. Santure M,P itre M,Nadeau Aet a. M etabolism . 2003
  • [6] l Action of novel antid iabeticthiazolid ined ione,T-174,in an imals of non-insulin-dependent d ia-betes mellitus(NIDDM)and in cultured muscle cells. Arakawa K,Ishihara T,Auto Met a. British Journal of Pharmacology . 1998
  • [7] l The metabolic syn-drome:Peroxisome proliferator-activated receptor gamma and itstherapeutic modulation. Gurnell M,Savage DB,Chatterjee VKet a. Journal of Clinical Endocrinology Metabolism The . 2003
  • [8] DRUGS
    HIDAKA HIROYOSHI
    TAKAGI MANABU
    MATSUZAKI TAKUSHI
    [P].
  • [9] Dual effect ofmetform in in cul-tured rat hepatocytes:potentiation of insulin action and preventionof insulin-induced insulin resistance. Melin B,Cherqu i G,B livetM Jet al. M etabolism . 1990